查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1836862

苯酮尿症治疗市场（按治疗类型、给药途径、年龄层和分销管道）—全球预测 2025-2032

Phenylketonuria Treatment Market by Treatment Type, Route of Administration, Age Group, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，苯酮尿症治疗市场将成长至 13.8505 亿美元，复合年增长率为 7.69%。

主要市场统计数据
基准年2024年 7.6513亿美元
预计2025年 8.2145亿美元
预测年份：2032年 1,385,050,000美元
复合年增长率（%） 7.69%

权威框架，重点关注苯酮尿症治疗重点，阐明临床要求、相关人员期望和策略决策途径

苯酮尿症 (PKU) 是一种独特的疾病，它融合了罕见疾病生物学、终身临床管理和不断发展的治疗创新。本书将读者置于当代背景：遗传学理解日益成熟，新生儿筛检已成为许多医疗保健系统的常规，患者权益倡导正在推动临床和商业性发展。本书首先强调了临床的核心挑战：持续降低苯丙胺酸水平、终生维持神经认知功能以及治疗依从性，这些都是影响长期生活品质的因素。

从相关人员的角度来看，临床医生、付款人和病患组织一致认为，我们需要治疗方法大幅减轻治疗负担，同时又能实现持续生化控制的疗法。同时，创新者和製造商正在应对复杂的监管途径、差异化的试验设计和新兴的真实世界证据需求。本引言概述了这些相关人员的优先事项如何汇聚成产品开发、卫生系统整合和公平取得的策略要务。在临床、商业和政策背景下进行讨论，有助于决策者评估后续章节，包括范式转移、关税影响、细分洞察、地理动态和可行建议。

深入概述分子生物学创新、不断发展的护理模式和付款人价值框架如何重塑苯酮尿症治疗的未来

苯酮尿症的治疗格局正在发生变革，这得益于分子医学的突破、医疗服务模式的转变以及支付方预期的不断变化。基因疗法和先进的酵素替代疗法已不再停留在理论阶段，而是正在进入临床阶段，并更加重视疗效的持久性、媒介安全性和长期监测。同时，药理学方法的创新旨在透过靶向代谢途径的药物来降低苯丙胺酸水平并改善认知功能，从而降低日常管理的复杂性。

这些治疗方法进展与营运模式的转变交织在一起。个人化营养管理日益受到数位监测和远端保健营养的支持，从而提高了依从性和纵向资料收集能力。付款人和卫生技术评估机构正在根据罕见疾病的情况调整其价值框架，除了生化指标外，更加重视患者报告的结果和功能终点。因此，临床开发计划和商业策略正转向整合护理模式，将治疗效益与依从性支持、诊断确认和核准后证据生成相结合。这些转变共同创造了新的商业性模式，并影响相关人员如何优先考虑投资、获取途径和生命週期规划。

对 2025 年美国关税改革如何影响苯酮尿症治疗的供应链策略、製造商决策和付款人合约动态的批判性分析

贸易和关税制度的政策变化可能对专科疗法、生产决策和供应链弹性产生深远影响。美国于2025年实施的关税调整促使PKU价值链上的相关人员重新评估其筹资策略、定价模式和库存计画。製造商正在透过评估供应商多元化来应对这一变化，以减轻成本负担，同时确保生技药品和复杂小分子药物的严格品质和合规性。

临床医生和卫生系统发现，在采购週期和报销讨论中，人们越来越关注医疗总成本以及依赖进口的供应链可能造成的价格洩漏。为此，一些开发商正在加快与肠外製剂和温敏酶疗法的本地製造合作伙伴的合作，或调整物流以优先考虑供应的连续性。同时，付款方优先考虑能够确保长期可负担性和可预测的可及性的合同，鼓励基于绩效的合同和风险分担安排。对于患者和权益倡导团体而言，一个关键问题是确保经济可行性，同时保持持续获得基本治疗方法的机会。这些动态正在重塑商业性谈判、供应商策略和业务计划，但不会改变个别病患照护的临床标准。

全面的细分主导整合，将治疗方式、给药途径、患者人口统计和分销管道与策略发展和获取考虑联繫起来

细緻入微的细分方法能够揭示临床需求、给药方式和通路动态的交会点，进而影响护理路径和商业机会。根据治疗类型，我们提供基因/酵素替代疗法、营养保健品和药物疗法，后者进一步细分为培维拉酶和盐酸沙丙蝶呤，每种疗法都有不同的临床特征、剂量需求和依从性。这些治疗差异指导临床医生如何根据不同严重程度选择介入措施，以及製造商如何定位差异化优势，例如起效时间、监测需求和长期安全性数据。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 扩大聚乙二醇化酶替代疗法可改善患者依从性和疗效
  • 开发针对 PAH 基因突变的基因编辑方法，提供一次性治疗方法
  • 旨在减少成人脑部苯丙胺酸摄取的大型中性胺基酸疗法的进展
  • 实现远端苯丙胺酸监测和饮食管理的数位健康平台的出现
  • 一家特殊饮食公司与一家生技公司之间的策略合作，为北大医学营养创新
  • 基于mRNA的治疗方法已获监管机构核准用于恢復PKU患者苯丙胺酸氧化酵素

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 苯酮尿症治疗市场（依治疗类型）

  • 基因治疗和酵素替代疗法
  • 营养补充品
  • 药物治疗
    • 聚乙二醇化酶
    • 沙丙蝶呤二盐酸盐

9. 苯酮尿症治疗市场（依给药途径）

  • 口服
  • 肠外

第 10 章。苯酮尿症治疗市场（依年龄层）

  • 成人（18岁以上）
  • 儿童（0-17岁）

第 11 章苯酮尿症治疗市场（依通路）

  • 医院药房
  • 网路药局
  • 零售药局
  • 专科诊所和治疗中心

12. 苯酮尿症治疗市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章苯酮尿症治疗市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章苯酮尿症治疗市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Abbott Laboratories
    • American Gene Technologies
    • APR Applied Pharma Research sa
    • BioMarin Pharmaceuticals Inc
    • Codexis, Inc.
    • Daiichi Sankyo Co. Ltd.
    • Galen Limited
    • Homology Medicines, Inc.
    • Nestle SA
    • PIAM Farmaceutici SPA
    • Pluvia AS
    • PTC Therapeutics, Inc.
    • Relief Therapeutics Holding SA
    • Sanofi group
    • Synlogic
    • Travere Therapeutics, Inc.
    • Ultragenyx Pharmaceutical Inc.
Product Code: MRR-030EE485160A

The Phenylketonuria Treatment Market is projected to grow by USD 1,385.05 million at a CAGR of 7.69% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 765.13 million
Estimated Year [2025] USD 821.45 million
Forecast Year [2032] USD 1,385.05 million
CAGR (%) 7.69%

A focused and authoritative framing of phenylketonuria treatment priorities that contextualizes clinical imperatives, stakeholder expectations, and strategic decision pathways

Phenylketonuria (PKU) represents a unique intersection of rare disease biology, lifelong clinical management, and advancing therapeutic innovation. This introduction situates readers within the contemporary landscape where genetic understanding has matured, newborn screening is routine in many health systems, and patient advocacy has catalyzed both clinical and commercial momentum. The narrative opens by clarifying core clinical challenges: durable reduction of phenylalanine levels, preservation of neurocognitive outcomes across the lifespan, and the practicalities of treatment adherence that influence long-term quality of life.

From a stakeholder perspective, clinicians, payers, and patient groups align around the need for therapies that meaningfully reduce treatment burden while delivering consistent biochemical control. At the same time, innovators and manufacturers are navigating complex regulatory pathways, differentiated trial designs, and emergent real-world evidence demands. This introduction outlines how these stakeholder priorities converge into strategic imperatives for product development, health system integration, and equitable access. By framing the discussion in clinical, commercial, and policy contexts, it prepares decision-makers to evaluate subsequent sections on shifting paradigms, tariff impacts, segmentation insights, geographic dynamics, and actionable recommendations.

An incisive overview of how molecular innovations, care model evolution, and payer value frameworks are reshaping the future of phenylketonuria treatment

The therapeutic landscape for phenylketonuria is undergoing transformative shifts driven by breakthroughs in molecular medicine, changing care delivery models, and evolving payer expectations. Gene therapy and advanced enzyme substitution approaches are no longer purely theoretical; they are progressing through clinical stages with growing attention on durability, vector safety, and long-term monitoring. Concurrently, innovations in pharmacological approaches aim to reduce daily management complexity, with agents targeting metabolic pathways to lower phenylalanine and improve cognitive outcomes.

These therapeutic advances intersect with operational shifts. Personalized nutrition management is increasingly supported by digital monitoring and telehealth-enabled dietetics, improving adherence and longitudinal data capture. Payers and health technology assessment bodies are adapting value frameworks to rare disease contexts, placing higher emphasis on patient-reported outcomes and functional endpoints alongside biochemical measures. As a result, clinical development plans and commercial strategies are reorienting toward integrated care models that bundle therapeutic benefits with adherence supports, diagnostic confirmation, and post-authorization evidence generation. Together, these shifts create new commercial archetypes and influence how stakeholders prioritize investment, access, and lifecycle planning.

A rigorous analysis of how tariff reforms in the United States in 2025 have influenced supply chain strategies, manufacturer decisions, and payer contracting dynamics in phenylketonuria care

Policy changes in trade and tariff regimes can have outsized implications for specialty therapies, manufacturing decisions, and supply chain resilience. The United States tariff adjustments introduced in 2025 have prompted stakeholders across the PKU value chain to reassess sourcing strategies, pricing models, and inventory planning. Manufacturers have responded by evaluating supplier diversification to mitigate cost exposure while maintaining stringent quality and regulatory compliance for biologics and complex small molecules.

Clinicians and health systems have observed that procurement cycles and reimbursement discussions are increasingly attentive to total cost of care and the potential for price leakage through import-dependent supply lines. In response, some developers have accelerated local manufacturing partnerships or adjusted logistics to prioritize continuity of supply for parenteral products and temperature-sensitive enzyme therapies. Concurrently, payers have signaled a greater focus on contracts that secure long-term affordability and predictable access, encouraging outcome-based agreements and risk-sharing arrangements. For patients and advocacy groups, the critical concern has been preserving uninterrupted access to essential therapies while ensuring affordability. Collectively, these dynamics are reshaping commercial negotiations, supplier strategies, and operational planning without altering clinical decision thresholds for individual patient care.

A comprehensive segmentation-driven synthesis that links therapeutic modality, administration route, patient age cohorts, and distribution channels to strategic development and access considerations

A nuanced segmentation approach reveals where clinical need, delivery modality, and channel dynamics intersect to influence care pathways and commercial opportunities. Based on Treatment Type, the landscape includes Gene Therapy & Enzyme Substitution Therapies, Nutritional Supplements, and Pharmacological Treatment, with the pharmacological category further delineated into Pegvaliase and Sapropterin Dihydrochloride, each with distinct clinical profiles, administration requirements, and adherence considerations. These therapeutic distinctions inform how clinicians select interventions across severity spectrums and how manufacturers position differentiated benefits such as onset of action, monitoring requirements, and long-term safety data.

Based on Route of Administration, the market is studied across Oral and Parenteral approaches, highlighting divergent patient experiences: oral regimens offer convenience and suitability for outpatient management, whereas parenteral modalities may deliver more potent biochemical control but require infrastructure for administration and monitoring. Based on Age Group, segmentation into Adults (18 years and above) and Pediatric (0-17 years) underscores the varying clinical objectives and support systems; pediatric care often centers on early developmental outcomes and family-centered adherence supports, while adult care emphasizes sustained neurocognitive functioning and comorbidity management. Based on Distribution Channel, the landscape includes Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, and Specialty Clinics & Treatment Centers, each channel presenting unique access considerations, payer interactions, and patient touchpoints for education, adherence reinforcement, and monitoring. Together, these segmentation dimensions create a matrix that companies and clinicians can use to align product attributes, service models, and go-to-market strategies with patient needs and healthcare system capabilities.

A strategic regional assessment showing how differing healthcare systems, screening programs, and manufacturing capabilities shape access to phenylketonuria therapies across global regions

Regional dynamics are central to understanding how clinical practice, regulatory pathways, and reimbursement systems influence the availability and adoption of PKU treatments. In the Americas, established newborn screening programs and concentrated centers of excellence support early diagnosis and longitudinal care, yet access challenges remain for patients outside metropolitan areas and for therapies that require specialized administration or monitoring. Policy dialogues in this region increasingly emphasize value-based contracting and expanded coverage for high-impact therapies, prompting manufacturers to design evidence-generation plans that resonate with payers as well as clinical stakeholders.

In Europe, Middle East & Africa, heterogeneity is pronounced: Western European markets typically exhibit mature reimbursement frameworks and organized patient registries that facilitate post-marketing evidence collection, while parts of the Middle East and Africa face infrastructure and access constraints that influence diagnostic reach and therapy adoption. Cross-border collaboration and capacity-building initiatives are emerging to address gaps in newborn screening and specialist care. In Asia-Pacific, rapid policy reform, investment in domestic biomanufacturing, and growing interest in rare disease policy are accelerating both clinical trial activity and localized supply chain strategies. Health systems in this region vary in their adoption of specialty therapies and in the development of reimbursement instruments tailored to rare disease treatments, which shapes manufacturer entry strategies and real-world evidence commitments.

An executive insight into how clinical data depth, manufacturing strategy, and integrated patient support offerings define competitive advantage among phenylketonuria therapy developers

Competitive dynamics in the phenylketonuria treatment landscape are shaped by product differentiation, clinical evidence depth, and ecosystem engagement strategies. Leading developers are investing in long-duration clinical studies and real-world evidence to demonstrate sustained biochemical control and functional outcomes, while also refining manufacturing processes to optimize scalability and cost-efficiency. Strategic partnerships with specialty clinics, patient advocacy organizations, and diagnostic laboratories are enhancing patient identification, enrollment in registries, and adherence support programs that complement therapeutic benefits.

Innovation in service delivery-such as integrated care pathways that link therapy initiation with nutritionists, digital monitoring tools, and telehealth follow-up-has become a competitive lever. Payers and provider networks are gravitating toward manufacturers who can offer comprehensive support bundles that reduce total cost of care and improve measurable patient outcomes. Additionally, companies pursuing advanced modalities are prioritizing regulatory engagement to clarify post-approval evidence requirements and to secure labeling that reflects long-term safety and functional benefits. Collectively, these approaches indicate that successful players will be those that pair robust clinical programs with pragmatic commercialization models and sustained stakeholder engagement.

A set of pragmatic, actionable recommendations that align clinical trial design, patient support services, supply resilience, and payer engagement to accelerate adoption and access

Industry leaders must align scientific ambition with pragmatic commercial and access strategies to ensure that therapeutic advances translate into measurable patient benefit. First, developers should prioritize study designs that include meaningful functional endpoints, patient-reported outcomes, and age-stratified analyses to satisfy both clinical and payer decision criteria. Second, integrating adherence-support services-digital monitoring, nutrition counseling, and telemedicine follow-up-can materially improve real-world outcomes and strengthen payer negotiations. Third, supply chain resilience should be built through supplier diversification, regional manufacturing partnerships, and contingency planning for temperature-sensitive and parenteral therapies.

Fourth, commercial teams should pursue outcome-based contracting pilots where feasible, coupling reimbursement to predefined clinical milestones that reflect patient-centered benefits. Fifth, collaboration with advocacy groups and specialist centers will accelerate patient identification and registries while enhancing post-approval surveillance. Finally, cross-functional alignment between regulatory, medical affairs, and market access teams will be critical to navigate evolving evidence expectations and to construct dossiers that balance long-term safety with real-world effectiveness. These combined actions will enhance adoption, preserve continuity of supply, and demonstrate value to payers and providers.

A transparent, multi-method research approach combining expert interviews, regulatory review, and literature synthesis to generate credible, actionable insights while acknowledging data limitations

This research synthesizes multiple evidence streams to produce balanced, reproducible insights. Primary research included structured interviews with clinical experts, specialty pharmacists, and patient advocacy leaders to capture frontline experiences of diagnosis, treatment initiation, and long-term management. Secondary research encompassed peer-reviewed literature, regulatory guidance documents, clinical trial registries, and health policy analyses to triangulate clinical efficacy, safety profiles, and evolving regulatory expectations. Data integrity was reinforced through cross-validation across sources, and methodological transparency was maintained by documenting interview protocols, inclusion criteria, and analytic frameworks.

Quantitative inputs were analyzed alongside qualitative insights to surface themes related to adherence, monitoring burdens, and payer considerations without projecting numerical estimates. Attention was given to temporal relevance by prioritizing sources and expert feedback from the most recent two-year horizon, ensuring that findings reflect current practice and policy shifts. Limitations were acknowledged; for example, regional heterogeneity in data availability and the inherent uncertainty around long-term outcomes for novel therapies were addressed by emphasizing robust evidence development pathways and adaptive post-authorization study designs. Overall, the methodology balances depth and credibility to inform strategic decisions across clinical, commercial, and policy domains.

A concise synthesis highlighting the interplay between clinical innovation, operational resilience, and stakeholder collaboration as the path to sustained patient benefit in phenylketonuria care

In conclusion, the phenylketonuria treatment landscape is at an inflection point where scientific progress intersects with practical imperatives for access and sustainability. Advances in gene therapy, enzyme substitution, and pharmacological options are expanding the therapeutic toolkit, but their full potential will be realized only through integrated strategies that address adherence, monitoring, and payer evidence needs. Supply chain and policy shifts, including tariff-related changes and regional manufacturing initiatives, underscore the importance of operational resilience alongside clinical innovation.

Going forward, successful stakeholders will be those who can translate clinical differentiation into durable real-world benefit through targeted evidence generation, robust patient support programs, and collaborative value propositions with payers and providers. Strengthening newborn screening, enhancing registries, and fostering multinational data-sharing will also be essential to characterize long-term outcomes and optimize care pathways. This conclusion synthesizes the report's core insights and points to concrete domains-clinical trial design, distribution strategies, and stakeholder engagement-where focused action can accelerate patient access and improve lifelong outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of pegylated enzyme substitution therapies improving patient adherence and outcomes
  • 5.2. Development of gene editing approaches targeting PAH gene mutations to provide one-time curative treatments
  • 5.3. Advances in large neutral amino acid therapies designed to reduce phenylalanine brain uptake in adults
  • 5.4. Emergence of digital health platforms enabling remote phenylalanine monitoring and dietary management
  • 5.5. Strategic partnerships between specialty diet companies and biotech firms to innovate PKU medical nutrition
  • 5.6. Regulatory approvals of mRNA-based therapies for phenylalanine hydroxylase restoration in PKU patients

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Phenylketonuria Treatment Market, by Treatment Type

  • 8.1. Gene Therapy & Enzyme Substitution Therapies
  • 8.2. Nutritional Supplements
  • 8.3. Pharmacological Treatment
    • 8.3.1. Pegvaliase
    • 8.3.2. Sapropterin Dihydrochloride

9. Phenylketonuria Treatment Market, by Route of Administration

  • 9.1. Oral
  • 9.2. Parenteral

10. Phenylketonuria Treatment Market, by Age Group

  • 10.1. Adults (18 years and above)
  • 10.2. Pediatric (0-17 years)

11. Phenylketonuria Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies
  • 11.4. Specialty Clinics & Treatment Centers

12. Phenylketonuria Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Phenylketonuria Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Phenylketonuria Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Abbott Laboratories
    • 15.3.2. American Gene Technologies
    • 15.3.3. APR Applied Pharma Research s.a.
    • 15.3.4. BioMarin Pharmaceuticals Inc
    • 15.3.5. Codexis, Inc.
    • 15.3.6. Daiichi Sankyo Co. Ltd.
    • 15.3.7. Galen Limited
    • 15.3.8. Homology Medicines, Inc.
    • 15.3.9. Nestle S.A.
    • 15.3.10. PIAM Farmaceutici S.P.A.
    • 15.3.11. Pluvia AS
    • 15.3.12. PTC Therapeutics, Inc.
    • 15.3.13. Relief Therapeutics Holding SA
    • 15.3.14. Sanofi group
    • 15.3.15. Synlogic
    • 15.3.16. Travere Therapeutics, Inc.
    • 15.3.17. Ultragenyx Pharmaceutical Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS PHENYLKETONURIA TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. PHENYLKETONURIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. PHENYLKETONURIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PHENYLKETONURIA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY GENE THERAPY & ENZYME SUBSTITUTION THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY GENE THERAPY & ENZYME SUBSTITUTION THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY GENE THERAPY & ENZYME SUBSTITUTION THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY GENE THERAPY & ENZYME SUBSTITUTION THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY GENE THERAPY & ENZYME SUBSTITUTION THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY GENE THERAPY & ENZYME SUBSTITUTION THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PEGVALIASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PEGVALIASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PEGVALIASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PEGVALIASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PEGVALIASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PEGVALIASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY SAPROPTERIN DIHYDROCHLORIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY SAPROPTERIN DIHYDROCHLORIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY SAPROPTERIN DIHYDROCHLORIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY SAPROPTERIN DIHYDROCHLORIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY SAPROPTERIN DIHYDROCHLORIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY SAPROPTERIN DIHYDROCHLORIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ADULTS (18 YEARS AND ABOVE), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ADULTS (18 YEARS AND ABOVE), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ADULTS (18 YEARS AND ABOVE), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ADULTS (18 YEARS AND ABOVE), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ADULTS (18 YEARS AND ABOVE), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ADULTS (18 YEARS AND ABOVE), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PEDIATRIC (0-17 YEARS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PEDIATRIC (0-17 YEARS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PEDIATRIC (0-17 YEARS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PEDIATRIC (0-17 YEARS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PEDIATRIC (0-17 YEARS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PEDIATRIC (0-17 YEARS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS & TREATMENT CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS & TREATMENT CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS & TREATMENT CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS & TREATMENT CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS & TREATMENT CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS & TREATMENT CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. AMERICAS PHENYLKETONURIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS PHENYLKETONURIA TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 97. AMERICAS PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 99. AMERICAS PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 101. AMERICAS PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 103. AMERICAS PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. AMERICAS PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. NORTH AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 110. NORTH AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 112. NORTH AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 114. NORTH AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. NORTH AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 118. NORTH AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. LATIN AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. LATIN AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 124. LATIN AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 126. LATIN AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. LATIN AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 130. LATIN AMERICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPE PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPE PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. MIDDLE EAST PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. MIDDLE EAST PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 160. MIDDLE EAST PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 162. MIDDLE EAST PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. MIDDLE EAST PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. MIDDLE EAST PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 172. AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 173. AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 174. AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 175. AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. AFRICA PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. ASEAN PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. ASEAN PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. ASEAN PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. ASEAN PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. ASEAN PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 198. ASEAN PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 199. ASEAN PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 200. ASEAN PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 201. ASEAN PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. ASEAN PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. ASEAN PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 204. ASEAN PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 205. GCC PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GCC PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GCC PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. GCC PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. GCC PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 210. GCC PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 211. GCC PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. GCC PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. GCC PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GCC PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GCC PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. GCC PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPEAN UNION PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPEAN UNION PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPEAN UNION PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPEAN UNION PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPEAN UNION PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPEAN UNION PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 229. BRICS PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. BRICS PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. BRICS PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. BRICS PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. BRICS PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 234. BRICS PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 235. BRICS PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 236. BRICS PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 237. BRICS PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. BRICS PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. BRICS PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. BRICS PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. G7 PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. G7 PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. G7 PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. G7 PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. G7 PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 246. G7 PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 247. G7 PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. G7 PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. G7 PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. G7 PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. G7 PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. G7 PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 253. NATO PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. NATO PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. NATO PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. NATO PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. NATO PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 258. NATO PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 259. NATO PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. NATO PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 261. NATO PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. NATO PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. NATO PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. NATO PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL PHENYLKETONURIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. UNITED STATES PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. UNITED STATES PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. UNITED STATES PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 270. UNITED STATES PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 271. UNITED STATES PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. UNITED STATES PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 273. UNITED STATES PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. UNITED STATES PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. UNITED STATES PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. UNITED STATES PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. CANADA PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. CANADA PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. CANADA PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 280. CANADA PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 281. CANADA PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. CANADA PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. CANADA PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. CANADA PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. CANADA PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. CANADA PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. MEXICO PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. MEXICO PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. MEXICO PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 290. MEXICO PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 291. MEXICO PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 292. MEXICO PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 293. MEXICO PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. MEXICO PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. MEXICO PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. MEXICO PHENYLKETONURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. BRAZIL PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. BRAZIL PHENYLKETONURIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. BRAZIL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 300. BRAZIL PHENYLKETONURIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 301. BRAZIL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 302. BRAZIL PHENYLKETONURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 303. BRAZIL PHENYLKETONURIA TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 304. BRAZIL PHENYLKETONURIA TREATMENT MARKET